2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)

Gregory Y.H. Lip (Chair)\textsuperscript{1,2,3*}, Jean-Phillippe Collet (Co-Chair)\textsuperscript{4}, Michael Haude (Co-Chair)\textsuperscript{5}, Robert Byrne\textsuperscript{6,7}, Eugene H. Chung\textsuperscript{8}, Laurent Fauchier\textsuperscript{9}, Sigrun Halvorsen\textsuperscript{10}, Dennis Lau\textsuperscript{11}, Nestor Lopez-Cabanillas\textsuperscript{12}, Maddalena Lettino\textsuperscript{13}, Francisco Marin\textsuperscript{14}, Israel Obel\textsuperscript{15}, Andrea Rubboli\textsuperscript{16}, Robert F. Storey\textsuperscript{17}, Marco Valgimigli\textsuperscript{18}, and Kurt Huber (Co-Chair)\textsuperscript{19}

\* Corresponding author. Tel: +44 121 5075080. E-mail address: g.y.h.lip@bham.ac.uk

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.

1 Institute of Cardiovascular Sciences, University of Birmingham, UK; 2 Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK; 3 Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark; 4 Sorbonne Université Paris 6. ACTION Study Group (www.action-coeur.org), Institut de Cardiologie Hôpital Pitié-Salpêtrière (APHP), INSERM UMRS, Paris, France; 5 Städtische Kliniken Neuss Lukaskrankenhaus GmbH Kardiologie, Nephrologie, Pneumologie, Neuss, Germany; 6 Deutsches Herz Zentrum Muenchen, Munich, Germany; 7 DZH K (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany; 8 University of North Carolina at Chapel Hill, Medicine, Cardiology, Electrophysiology, Chapel Hill, NC, USA; 9 Centre Hospitalier Universitaire Trousseau et Faculté de Médecine—Université François Rabelais, Tours, France; 10 Department of Cardiology, Oslo University Hospital Ulleval, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 11 Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia; 12 Clinic Advenista Belgrano, Instituto Del Corazon, Buenos Aires, Argentina; 13 Cardiology Department, Humanitas Research Hospital, Rozzano, MI, Italy; 14 Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; 15 Milsark Hospital, Cardiology Unit, Johannesburg, South Africa; 16 Division of Cardiology, Laboratory of Interventional Cardiology, Ospedale Maggiore, Bologna, Italy; 17 Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; 18 Inselspital, Cardiology, Bern, Switzerland; 19 Third Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelmshospital Vienna, Vienna, Austria; 20 School of Medicine, Belgrade University, Cardiology Clinical Clinic, Clinical Centre of Serbia, Belgrade, Serbia; 21 Department of Medical Science and Cardiology, Uppsala University, Uppsala, Sweden; 22 Cardiology Department, Maastricht UMC+, Maastricht, Netherlands; 23 University Heart Center Zurich, Zurich, Switzerland; 24 Antwerp University and University Hospital, Antwerp, Belgium; 25 Department of Cardiology, Clinical Center of Serbia, Belgrade, Serbia; 26 Turku University Hospital, Cardiology, Department of Internal Medicine, Turku, Finland; 27 St. Antonioius Hospital, Cardiology Department, Nieuwegein, Netherlands; 28 Ferrarotomo Hospital, Azienda Ospedaliero-Utivico Policlinico-Vittorio Emanuele, University of Catania, Cardiologia Department, University of Catania, Catania, Italy; 29 Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Senior Interventional Cardiologist, Uppsala University Hospital, Uppsala, Sweden; 30 Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernandez Almagro, Madrid, Spain; 31 Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain; 32 Department of Cardiology, Leiria Hospital Centre, Portugal; 33 Oberarzt Medizinische Klinik und Poliklinik I, Ludwig-Maximilians-Universität (LMU), Campus Großhadern, Muenchen, Germany; 34 Department of Pharmacology, Catholic University School of Medicine, Rome, Italy; 35 Ta Tsui Medical University, Tai Pei, Taiwan; 36 Cardiology Department, University of Washington, Seattle, USA; 37 OU Heart Rhythm Institute, OU Health Sciences Center, Oklahoma, USA; 38 Instituto Nacional de Cardiologia I. Chavez, Electrofisiologia, Mexico, DF, Mexico; and 39 Unimed Hospital, Benoni, South Africa

Received 25 June 2018; editorial decision 28 June 2018; accepted 28 June 2018

In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.

Keywords

European Heart Rhythm Association • Consensus document • Position paper • Atrial fibrillation • Acute coronary syndrome • Coronary artery disease • Myocardial infarction • Percutaneous coronary intervention • Stent • Antithrombotic therapy • Antiplatelet agents • Anticoagulation • Vitamin K antagonists • Non-vitamin K antagonist oral anticoagulants • Low molecular weight heparin • Parenteral anticoagulants • Left atrial appendage occlusion • Stroke • Thromboembolism • Thrombosis • Bleeding

Table of Contents

Introduction ......................................................... 3
Evidence review .................................................... 3
An overview of new data since last version of the document ........ 3
Observational cohorts ........................................... 3
New randomized controlled trials on antithrombotic therapy ....... 4
Oral anticoagulants .............................................. 4
Antiplatelet drugs ............................................... 5
Parenteral anticoagulants ..................................... 7
Evidence review

This document was prepared by the Task Force with representation from EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, LAHRS and CASSA, and peer-reviewed by official external reviewers representing all these bodies. Their members made a detailed literature review, weighing the strength of evidence for or against a specific treatment or procedure, and including estimates of expected health outcomes where data exist. In controversial areas, or with respect to issues without evidence other than usual clinical practice, a consensus was achieved by agreement of the expert panel after thorough deliberation.

We opted for an easier and user-friendly system of ranking using ‘coloured hearts’ that should allow physicians to easily assess the current status of the evidence and consequent guidance (Table 1). This EHRA grading of consensus statements does not have separate definitions of the level of evidence. This categorization, used for consensus statements, must not be considered as directly similar to that used for official society guideline recommendations, which apply a classification (Class I–III) and level of evidence (A, B, and C) to recommendations used in official guidelines.

Thus, a green heart indicates a ‘should do this’ consensus statement or indicated treatment or procedure that is based on at least one randomized trial, or is supported by strong observational evidence that it is beneficial and effective. A yellow heart indicates general agreement and/or scientific evidence favouring a ‘may do this’ statement or the usefulness/efficacy of a treatment or procedure. A ‘yellow heart’ symbol may be supported by randomized trials based on a small number of patients or which is not widely applicable. Treatment strategies for which there is scientific evidence of potential harm and should not be used (‘do not do this’) are indicated by a red heart.

Table 1: Indication for PCI

<table>
<thead>
<tr>
<th>Indication for PCI</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>elective PCI</td>
<td>green heart</td>
</tr>
<tr>
<td>post-procedural</td>
<td>green heart</td>
</tr>
<tr>
<td>post-discharge</td>
<td>green heart</td>
</tr>
<tr>
<td>long-term management</td>
<td>green heart</td>
</tr>
</tbody>
</table>

An overview of new data since last version of the document

Observational cohorts

Since the publication of the last consensus document, at least 30 observational reports on patients on oral anticoagulation (OAC) presenting with ACS and/or undergoing PCI have been published.8–37

Supplementary material online, Table Sw1.

A total of 171,026 patients have been included, with AF being the most frequent, albeit not the only, indication for OAC. For 29,418 patients, information on the different antithrombotic strategies was provided: 7656 (26%) received triple antithrombotic therapy (TAT) of OAC, aspirin and a P2Y₁₂-receptor inhibitor (generally clopidogrel), 21,279 (72%) DAPT of aspirin and P2Y₁₂-receptor inhibitor (generally clopidogrel), and 483 (2%) dual antithrombotic therapy (DAT) of OAC and either aspirin or clopidogrel. In all studies, except three14,15,21, where approximately 50%, 39%, and 8% of patients, respectively, received a NOAC as part of the antithrombotic regimen, OAC consisted of a vitamin K-antagonist (VKA), generally warfarin.8–37
tic range (TTR) for patients receiving a VKA. The bleeding risk is inversely related to the quality of OAC, measured as time in therapeutic antithrombotic regimens. The risk of (major) bleeding may be increased risk of total and/or major bleeding compared with other antithrombotic combinations. The rates of major adverse cardiovascular events (MACCE) and associated selection bias in the prescription of the various antithrombotic regimens, as well as the lack of systematic bleeding risk assessment, incomplete information on adherence to treatment and TTR values, the independent contribution of periprocedural management on the occurrence of MACCE and bleeding, and the alterations in the prescribed antithrombotic therapy subsequent to an ischaemic event have to be interpreted with caution as this registry study was small and not randomized. The use of the newer, more potent P2Y₁₂-receptor inhibitors, prasugrel and ticagrelor as part of a TAT regime, has been associated with an increased risk of bleeding events. No specific information on the relative efficacy and safety of NOACs, either as a category or as individual agents, can be derived from available observational data. Further data are expected to come from the observational, multicentre AVIATOR 2 registry. This study was capped after including 500 (of the originally planned 2500) AF patients undergoing PCI and evaluates MACCE and bleeding rates.

### New randomized controlled trials on antithrombotic therapy

#### Oral anticoagulants

Since publication of the 2014 consensus document, two randomized controlled trials on NOAC vs. VKA in combination with antiplatelets for patients with AF undergoing PCI have been published primarily investigating safety, and at least two large trials are ongoing.

In the randomized PIONEER AF PCI trial (Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban, and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with Atrial Fibrillation who Undergo Percutaneous Coronary Intervention), 2124 participants with non-valvular AF who had undergone PCI with stenting (about 30% of patients had a troponin-positive ACS and about 20% had unstable angina as index event) were randomly assigned to DAT with ‘low-dose’ rivaroxaban [15 mg od (once daily)] plus a P2Y₁₂ inhibitor for 12 months (Group 1), novel TAT with ‘very-low-dose’ rivaroxaban [2.5 mg bid (twice daily)] plus DAPT for 1, 6, or 12 months (Group 2), or standard therapy with a dose-adjusted VKA (od) plus DAPT for 1, 6, or 12 months (Group 3).

---

**Table 1** Scientific rationale of recommendations

<table>
<thead>
<tr>
<th>Definitions where related to a treatment or procedure</th>
<th>Consensus statement instruction</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific evidence that a treatment or procedure is beneficial and effective. Requires at least one randomized trial or is supported by strong observational evidence and authors’ consensus (as indicated by an asterisk).</td>
<td>‘Should do this’</td>
<td><img src="https://via.placeholder.com/15" alt="Heart" /></td>
</tr>
<tr>
<td>General agreement and/or scientific evidence favour the usefulness/efficacy of a treatment or procedure. May be supported by randomized trials based on a small number of patients or which is not widely applicable.</td>
<td>‘May do this’</td>
<td><img src="https://via.placeholder.com/15" alt="Heart" /></td>
</tr>
<tr>
<td>Scientific evidence or general agreement not to use or recommend a treatment or procedure.</td>
<td>‘Do not do this’</td>
<td><img src="https://via.placeholder.com/15" alt="Heart" /></td>
</tr>
</tbody>
</table>

*This categorization for our consensus document should not be considered as being directly similar to that used for official society guideline recommendations which apply a classification (I–III) and level of evidence (A, B, and C) to recommendations.*
The primary endpoint of the trial was clinically-significant bleeding. The rates of clinically-significant bleeding were lower in the two groups receiving rivaroxaban than in the group receiving standard therapy (16.8% in Group 1, 18.0% in Group 2, and 26.7% in Group 3; \( P < 0.001 \) for both comparisons). There were no statistically significant differences in the rates of death from cardiovascular causes, myocardial infarction (MI), or stroke, although the study was not powered for efficacy and the observed broad confidence intervals (CIs) diminish the surety of any conclusions. No power calculation in this exploratory trial, recruitment was not event-driven, and that prior stroke was an exclusion criteria (which led to the selection of low risk patients).

In the Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (RE-DUAL PCI) study,\(^{39,40}\) DAT with dabigatran etexilate (110 or 150 mg bid) and a P2Y\(_{12}\) inhibitor (either clopidogrel or ticagrelor) was compared with TAT with warfarin, a P2Y\(_{12}\) inhibitor, irrespective of concomitant aspirin use.\(^{41}\) However, no stroke or systemic embolism and major bleeding compared with the 110 mg bid dose compared with TAT. Two dabigatran groups separately, there was a non-significant excess combined when compared with 13.4% in the TAT group (HR 1.04, 0.72, 95% CI 0.58–0.88; \( P \) 0.72) which did not include elderly patients outside the United States (HR 0.72, 95% CI 0.36–0.85).\(^{42}\) There was no difference in the major adverse cardiac events (MACE) (10.4% vs. 10.0%, HR 0.85, 95% CI 0.48–1.29), or in individual outcomes of all-cause mortality, cardiac death, MI, stent thrombosis, or stroke between DAT and TAT.

### Antiplatelet drugs

The WOEST study initially tested the concept of dropping aspirin after PCI and using a combination of clopidogrel and warfarin alone, suggesting that this approach is effective and safe in terms of thrombotic events, and reduced overall bleeding risk.\(^{43}\) As discussed above, the PIONEER and RE-DUAL trials\(^{39,40}\) further reinforce the concept of potential redundancy of aspirin and its associated bleeding hazard in AF patients treated with anticoagulant and P2Y\(_{12}\) inhibitor.

Although in a non-AF population, the GEMINI-ACS-1 study has reinforced the concept that oral anticoagulation may substitute for aspirin in patients who are stable early after PCI, showing that rivaroxaban combined with either clopidogrel or ticagrelor provided similar efficacy in prevention of ischaemic events compared with aspirin with either of these P2Y\(_{12}\) inhibitors.\(^{44}\) The COMPASS study demonstrated higher efficacy of rivaroxaban 2.5 mg bid plus aspirin 100 mg od in long-term prevention of ischaemic events vs. aspirin alone, in a non-AF vascular disease population. This was accompanied by higher bleeding complications when compared with aspirin alone, and does not support the suggestion that aspirin can be substituted by an OAC.\(^{45}\) The GLOBAL-LEADERS study is assessing, amongst other concepts, whether ticagrelor monotherapy from 1 month after PCI is superior to standard DAPT and will further define the necessity of aspirin from this timepoint in a non-AF population.\(^{46}\) TWILIGHT is the largest study to date that is designed and powered in order to demonstrate a lower bleeding rate with ticagrelor monotherapy vs. ticagrelor plus acetylsalicylic acid (ASA) beyond 3 months post-procedure in a high-risk patient population undergoing PCI with drug-eluting stents (DES).\(^{47}\)

Overall, limited numbers of patients have been studied with the combination of an anticoagulant and either prasugrel or ticagrelor. Because of the greater platelet inhibition with approved doses of prasugrel or ticagrelor compared with clopidogrel, the risk...
Table 2  Randomized trials comparing NOAC vs. VKA in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Study design</th>
<th>Size (n)</th>
<th>Comparison</th>
<th>Summary of findings</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Published RCTs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gibson et al. [39] (PIONEER AF PCI)</td>
<td>RCT Open-label (exploratory without statistical power calculation)</td>
<td>2124</td>
<td>15 mg rivaroxaban od plus a P2Y12 inhibitor for 12 months, very-low-dose rivaroxaban (2.5 mg bid) plus dual antiplatelet therapy (DAPT) for 1, 6, or 12 months, or standard therapy with a dose-adjusted vitamin K antagonist (od) plus DAPT for 1, 6, or 12 months</td>
<td>Rates of clinically significant bleeding were lower in the two groups receiving rivaroxaban than in the group receiving standard therapy with VKA (16.8% vs. 26.7% and 18.0% vs. 26.7%; ( P &lt; 0.001 ) for both comparisons)</td>
<td>Not powered for efficacy</td>
</tr>
<tr>
<td>Cannon et al. [39,40] (RE-DUAL PCI)</td>
<td>RCT Open-label PROBE design</td>
<td>2725</td>
<td>Dual antithrombotic therapy with dabigatran etexilate (110 mg or 150 mg bid) plus clopidogrel or ticagrelor is compared with triple therapy with warfarin</td>
<td>ISTH major or CRNM bleeding was significantly lower in the two groups receiving dual therapy with dabigatran than in the group receiving triple therapy with warfarin (15.4% vs. 26.9% and 20.2% vs. 25.7%) (HR 0.52; 95% CI 0.42–0.63 and HR 0.72; 95% CI 0.58–0.88, respectively)</td>
<td>Not powered for efficacy</td>
</tr>
<tr>
<td>Ongoing RCTs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUGUSTUS [41] (NCT02415400)</td>
<td>RCT Open-label, 2 x 2 factorial design</td>
<td>4600 patients with ACS or PCI</td>
<td>Two randomization steps include (i) Apixaban (5 mg bid) vs. VKA based triple antithrombotic therapy and (ii) Aspirin vs. Aspirin Placebo</td>
<td>Primary outcome: ISTH major or CRNM bleeding during the treatment period</td>
<td>Enrolment completed April 2018</td>
</tr>
<tr>
<td>ENTRUST-AF-PCI [43] (NCT02866175)</td>
<td>RCT</td>
<td>1500</td>
<td>Edoxaban-based regimen (60 mg od) is compared with a VKA based triple antithrombotic therapy</td>
<td>Primary outcome: ISTH major or CRNM bleeding during the treatment period</td>
<td>Estimated completion 2019</td>
</tr>
</tbody>
</table>

ACS, acute coronary syndrome; CRNM, clinically relevant non-major; CI, confidence interval; DAPT, dual antiplatelet therapy; HR, hazard ratio; ISTH, International Society on Thrombosis and Haemostasis; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist; PCI, percutaneous coronary intervention; PROBE, prospective open-label blinded event adjudication; RCT, randomized clinical trial.
of spontaneous bleeding is higher when used in combination with aspirin.\(^{51,52}\)

The PEGASUS-TIMI 54 study assessed a lower dose of ticagrelor (60 mg bid) in addition to the 90 mg bid dose licensed for use in ACS in combination with aspirin (75–150 mg od) in non-AF patients within 1–3 years of MI and at higher risk of recurrent atherothrombotic events.\(^{53}\) Both doses of ticagrelor had similar efficacy and safety although there were numerical trends suggesting less minor bleeding and better tolerability with ticagrelor 60 mg bid.\(^{54}\) Interestingly, the extent of platelet inhibition with ticagrelor 60 mg bid was similar to that achieved with ticagrelor 90 mg bid.\(^{55}\) The TROPICAL-ACS study suggested that guided de-escalation from prasugrel to clopidogrel (in clopidogrel responders) after PCI is non-inferior to continuing prasugrel in a DAPT strategy.\(^{56}\) Another de-escalation trial (TOPIC) compared a switch from DAPT (aspirin plus a new P2Y12-inhibitor) with conservative DAPT (aspirin plus clopidorel) 1 month after ACS or to continue their initial drug regimen (unchanged DAPT).\(^{57}\) These authors reported that switched DAPT is superior to an unchanged DAPT strategy to prevent bleeding complications without increase in ischaemic events following ACS, although these studies were not powered to compare ischaemic event rates. However, the implications of poor response to clopidogrel in patients treated with clopidogrel and an anticoagulant, rather than aspirin, are not well characterized.

### Parenteral anticoagulants

Recent meta-analysis of 2325 VKA-treated AF patients undergoing coronary angiography with or without PCI showed that both bleeding and 30-day major adverse cardiovascular event rates were similar between those with interrupted or uninterrupted VKA.\(^{58}\) However, those who received parenteral bridging anticoagulants on interruption of VKA had higher major bleeding rates.\(^{58}\) The above data confirm recommendations of uninterrupted anticoagulation for elective PCI.\(^{1}\) At present, little is known regarding the bleeding and MACCE rates with continuation or interruption of NOAC during PCI.

Limited data exists to guide the choice of and the dose of parenteral anticoagulants, whether unfractionated heparin (UFH), bivalirudin, or enoxaparin and their optimal dosages, specific to AF patients already taking OAC when undergoing PCI for ACS. Additional parenteral anticoagulants may not be needed, particularly if the international normalized ratio (INR) is more than 2.5 at the time of elective PCI.\(^{59}\) On the other hand, the usage of parenteral anticoagulants during PCI is recommended in AF patients on NOAC regardless of the timing of the last NOAC dose.\(^{59}\)

### Stents in patients with increased bleeding risk

#### Drug-eluting and bare-metal stents

Since December 2014, three large-scale trials, comparing different stents, have enrolled relatively high proportions of patients with AF requiring treatment with OAC. One trial enrolled patients regarded as being uncertain candidates for DES at the time.\(^{60}\) About 12% had OAC at discharge. This pre-specified post hoc analysis of the ZEUS trial demonstrated that the use of the Endeavor zotarolimus-eluting stent is superior to bare-metal stents in terms of the composite of death, MI and target vessel revascularization (TVR) (HR 0.76, 95% CI 0.61–0.95; P = 0.011) in patients at high bleeding risk (mainly triggered by TVR).\(^{60}\) The median duration of DAPT was 1 month.

Another prospective randomized trial enrolled patients at high bleeding risk and randomly allocated treatment with a polymer-free biolimus A9-DES vs. a bare-metal stent (LEADERS FREE trial).\(^{61}\) The main finding was that the primary safety endpoint of death, MI, and stent thrombosis was reduced with the biolimus A9-DES (HR 0.71, 95% CI 0.56–0.91; P = 0.001 for non-inferiority and P = 0.005 for superiority). In line with expectations, the primary efficacy endpoint of target lesion revascularization was reduced by half with the biolimus A9-DES (HR 0.50, 95% CI 0.37–0.69; P < 0.001), while death as single endpoint was not reduced. Treatment effects were consistent in patients with planned OAC therapy at discharge for efficacy and safety endpoints.

Subgroup analysis demonstrated similar outcome data for the biolimus A9-DES vs. bare-metal stents in elderly patients; there was evidence of interaction with regard to treatment effect and diagnosis of ACS at baseline in relation to the primary safety endpoint (P = 0.04) with greater benefit for patients treated with the biolimus A9-DES.\(^{62}\) Safety and efficacy were maintained during an extended follow-up out to 2 years, even amongst the subgroup of patients who were candidates for long term OAC.\(^{63,64}\)

A more recent clinical trial compared the outcomes of elderly patients (>75 years) undergoing PCI with a new generation DES (biodegradable polymer everolimus-eluting stents) compared with bare-metal stents (SENIOR trial), where 17.6% had AF at enrolment.\(^{65}\) DAPT was recommended in both groups for the same duration: 1 month in patients with stable angina and 6 months in patients with ACS. The composite of death, MI, stroke, or target lesion revascularization was significantly reduced in patients treated with DES (relative risk 0.71, 95% CI 0.52–0.94; P = 0.02). Bleeding was similar in both groups, in line with the identical recommendations for antithrombotic treatment in both groups.

Results with new-generation DES are generally excellent across the spectrum of patient and lesion subgroups. A recent systematic review of 158 trials—conducted as part of a ESC-EAPC1 task force on the evaluation of coronary stents—reported low rates of both restenosis and stent thrombosis at 9–12 months with new-generation DES (less than 5% and 1%, respectively), with lower rates compared with both bare-metal stents and early-generation DES.\(^{66}\) Large-scale registries support the generally high efficacy and safety of new-generation DES. Convincing data to support different durations of DAPT according to stent type are lacking and the general recommendation for 1-month DAPT after bare-metal stenting in stable patients is not well supported. More recently, drug-eluting balloons can be an alternative for stenting in special lesions (e.g. in patients with in-stent restenosis).

The 2017 ESC Focused Update on Antiplatelet Therapy recommends that choice of duration of DAPT in patients should no longer be differentiated on basis of device used, i.e. whether the stent implanted at time of PCI is a DES or bare-metal stent, or whether a drug eluting balloon is used.\(^{5}\) In view of the superior antiplatelet efficacy and no signal of higher thrombotic risks even after short term DAPT duration of new generation DES when compared with BMS, it is recommended that patients with AF undergoing PCI should be treated with new generation DES.
Bioresorbable scaffolds

Bioresorbable scaffolds (BRS) are rarely used in clinical practice at present, due to an increased risk of target lesion failure and device thrombosis at 2–3 year follow-up and an excess of 1-year target vessel MI and stent thrombosis in comparison with conventional DES.88

Consensus statements

- In view of the superior anti-restenotic efficacy and no signal of higher thrombotic risk of new-generation DES it is recommended that patients with AF undergoing PCI should be treated with new generation DES
- Choice of DAPT duration should not be differentiated based on whether the stent implanted at time of PCI is a DES or bare-metal stent
- Patients requiring oral anticoagulation should not receive BRS

DES, drug-eluting stent; DAPT, dual antiplatelet therapy; BRS, biovascular scaffold.

Other data in structural interventions, i.e. valve interventions (TAVI, mitral), left atrial appendage closure

Transcatheter aortic valve implantation

Cerebral embolization is one of the major complications that might occur in the very early phase of valve placement. New periprocedural cerebral ischaemic defects have been reported in more than 60% of patients, and clinically-apparent stroke occurs in around 3% of cases on average (range 0–6%).59

Despite a higher incidence of cerebrovascular events with the first devices in the PARTNERS trials,70–71 there seems to be a similar risk of stroke in patients undergoing TAVI compared with patients receiving the surgical aortic valve replacement (SAVR).72–75 Parenteral antithrombotic treatment during TAVI aims to prevent thromboembolic complications related to large catheter manipulation, guidewire insertion, balloon aortic valvuloplasty, and valve prosthesis implantation, while minimizing the risk of bleeding, particularly at the vascular access site. Based on retrospective studies and randomized trials,72,73,76,77 the most commonly used anticoagulant is UFH at doses of 50–70 IU/kg with a target activated clotting time (ACT) of 250–300 s, although no optimal ACT has been defined, even in guidelines.78–82 Given the higher cost and similar efficacy of bivalirudin when compared with UFH, the latter should remain the standard of care for patients undergoing TAVI unless contra-indications to UFH, such as known heparin-induced thrombocytopenia, exist.83

Subacute cerebrovascular events associated with TAVI occur between 24 h and 30 days, while all the episodes occurring after 30 days are defined as late. Stroke rate at 30 days reported by randomized clinical trials and registries ranges from 0% to 9%.84 Factors potentially involved in such cerebrovascular events development are: thrombogenicity of the valve apparatus, exposure of the stent struts (expanded together with the valve), persistence of the perivalvular space occupied by the native valve and the development of paroxysmal atrial arrhythmias.69,85 Moreover, the baseline risk for ischaemic and thromboembolic complications is further increased by comorbidities including concomitant CAD, which is present in 20–70% of patients and requires PCI in 20–40% of patients. Furthermore, AF is found in about one-third of patients referred for TAVI.70,71,85–87

Prospective data on antithrombotic therapy after TAVI are still scarce and recommendations regarding choice and optimal duration of antiplatelet or antithrombotic therapy are largely based on experience from PCI and open-heart aortic valve replacement.

Among patients without CAD and without AF, the current standard of care is still DAPT consisting of low-dose aspirin (75–100 mg per day) and clopidogrel 75 mg od (after loading dose of 300–600 mg), both started within 24 h prior to the intervention, and continued for 3–6 months followed by indefinite aspirin monotherapy. Patients receiving single antiplatelet therapy soon after TAVI tended to have a lower rate of major adverse events after the intervention when compared with patients on DAPT, with a significant reduction of major and life-threatening bleeding complications at three months follow-up.88 A meta-analysis of the pooled results of this trial and other minor studies showed no benefit of DAPT in early stroke reduction with a trend towards an increase in major bleeding, thus suggesting the opportunity to adopt an antiplatelet monotherapy soon after the intervention for all patients without indication for anticoagulation.59

Other clinical trials are currently ongoing. The Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation (POPular TAVI, n = 1000) trial is currently exploring whether it is possible to skip clopidogrel in a larger population of patients undergoing TAVI with or without an indication for OAC prior to the procedure. Patients are randomized to aspirin alone vs. aspirin plus clopidogrel for the first 3 months after the procedure and evaluated for the primary safety endpoint of freedom of non-procedure-related bleeding complications at 1 year follow-up. The cohort of patients for whom OAC is indicated (AF, mechanical valve prostheses) is randomized to clopidogrel plus OAC vs. OAC alone (NCT02247128).

The Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antiplatelet-based Strategy after Transcatheter aortic valve replacement to Optimize Clinical Outcome (Galileo, n = 1520) study is an open-label, multicentre, randomized controlled trial actively recruiting patients undergoing TAVI with no indication to permanent anticoagulant therapy. Patients assigned to the OAC arm are randomly assigned to receive 10 mg od rivaroxaban up to 25 months plus low-dose aspirin during the first 3 months in order to assess whether this strategy is superior to DAPT with aspirin plus clopidogrel (for 3 months) followed by aspirin alone in reducing death or first clinical thromboembolic events with no increase in bleeding complications (NCT02556203).70
Third, the Anti-Thrombotic Strategy after Trans-Aortic Valve Implantation for Aortic Stenosis (ATLANTIS, n = 1509) trial is evaluating whether an anticoagulant-based strategy with apixaban 5 mg bid is superior to standard-of-care therapy in preventing death, MI, stroke, systemic embolism, intracardiac or bioprosthesis thrombus formation, or life-threatening/major bleeding complications at 1 year follow-up in patients successfully treated with a TAVI procedure. The ATLANTIS trial will include two different populations: patients with an indication for anticoagulation, where standard of care is represented by a VKA and patients for whom an antplatelet regimen with aspirin plus clopidogrel is the first-choice antithrombotic treatment. Randomization is consequently stratified according to the need (or no need) for anticoagulation for clinical reasons other than TAVI itself (NCT02664649).

Finally, another study that aims at demonstrating the superiority of a single anticoagulant vs. the combination of an anticoagulation plus aspirin with respect to a net clinical benefit endpoint at 1 year (the AVATAR trial, NCT02735902) has been announced (n = 170).

Among TAVI patients with AF but without CAD, OAC is recommended in accordance with recommendations for AF alone. Whether the addition of antplatelet therapy to OAC is required in this context remains to be determined. The existing experience with patients receiving biological aortic valve replacement suggests that OAC alone may be sufficient to prevent thrombotic events. Indeed, OAC (essentially VKA) use in surgically implanted biological aortic valves is generally recommended for only 3 months and can be stopped thereafter, except where patients have other reasons for prolonged or life-long OAC.

The POOPular TAVI trial, which is currently recruiting patients, will provide information regarding the safety and the net clinical benefit of a VKA alone vs. the combination of clopidogrel plus a VKA in patients undergoing TAVI who have an indication to permanent OAC. With reference to the life-long use of a NOAC compared with VKA, beyond the reported ATLANTIS trial, the Edoxaban Compared to Standard Care after Heart Valve Replacement Using a LAA closure device in a randomized controlled fashion. It is currently the only percutaneous device approved in both Europe and the US.

In the PROTECT-AF trial, patients were treated with warfarin and aspirin 81 mg for 45 days post-procedure, then with aspirin and clopidogrel for 6 months, and then with aspirin indefinitely. In the PREVAIL study, patients were on warfarin plus aspirin 81 mg for the first 45 days, then on aspirin 325 mg plus clopidogrel until post-operative month 6 (in the absence of any clot), then on aspirin 325 mg alone. Thus, PROTECT and PREVAIL did not enroll patients unable to take OACs, but patients who were at least able to take warfarin for 45 days post-procedure. This contradicts the current suggested indication to use a LAA closure device in patients with contraindications against OACs. Moreover, the efficacy and safety of using a NOAC instead of warfarin was not assessed in these two major trials.

These trials have been subject to much debate, with reports of device related thrombus that can lead to thromboembolism. In the absence of clinically relevant LAA leaks, OAC can be discontinued and the patient treated with DAPT or a single antiplatelet therapy for at least 6 months after the procedure, although some cardiologists continue single antiplatelet therapy long term. There are also no data to suggest the optimal management of an AF patient with left atrial appendage occlusion who requires a cardioversion. A transoesophageal echocardiogram (TOE) assessment for thrombus may be performed, and a shorter duration of anticoagulation similar to TOE-guided cardioversion protocol may be considered.

**Mitral intervention**

No study has addressed the optimal antithrombotic regimen after percutaneous edge-to-edge transcatheter mitral valve repair (e.g. MitraClip system, Abbott, Abbott Park, IL, USA). Pivotal studies have mandated the use of aspirin for at least 6 months in combination with clopidogrel for 1–3 months in patients without AF while patients with AF are treated with OAC plus aspirin.

Transcatheter mitral valve implantation (TMVI) with a transcatheter mitral valve prosthesis has been performed in patients with surgical degenerated bioprostheses [valve-in-valve (ViV)] or with recurrent MR following mitral repair annuloplasty [valve-in-ring (ViR)]. There is currently limited evidence that adding a single antiplatelet therapy or DAPT to OACs further decreases the risk of symptomatic or asymptomatic valve thrombosis.

**Left atrial appendage closure**

The left atrial appendage (LAA) is implicated in approximately 90% of strokes in patients with AF. Left atrial appendage occlusion, either percutaneous or surgical, is a rapidly-emerging option for patients who cannot take long-term OAC. Of the percutaneous options, the WATCHMAN (Boston Scientific) device is so far the only tested device for LAA closure in a randomized controlled fashion. It is currently the only percutaneous device approved in both Europe and the US.

The data on Amplatzer Cardiac Plug (now Amulet), are largely based on registry studies. The data on Amplatzer Cardiac Plug (now Amulet), are largely based on registry studies. The most recent study had 18.9% patients on either a VKA or NOAC immediately post-procedure. In a study of 52 Canadian patients receiving this device, there was an only 1.9% rate of stroke when antiplatelets alone were used post-procedure during a mean follow-up of 20 ± 5 months.

**Amplatzer**

The data on Amplatzer Cardiac Plug (now Amulet), are largely based on registry studies. The data on Amplatzer Cardiac Plug (now Amulet), are largely based on registry studies. The most recent study had 18.9% patients on either a VKA or NOAC immediately post-procedure. In a study of 52 Canadian patients receiving this device, there was an only 1.9% rate of stroke when antiplatelets alone were used post-procedure during a mean follow-up of 20 ± 5 months.

**Lariat**

The LARIAT device (SentreHeart) ligates off the LAA via a combined trans-septal and epicardial approach. It received FDA approval for soft tissue closure but not specifically for LAA closure. It has not been tested in a randomized controlled trial, so efficacy data are
Assessing stroke and bleeding risks

The CHA2DS2-VASc has been widely used worldwide for stroke risk stratification in AF, even in patients with coronary artery disease treated with coronary stenting. Other less established risk factors for stroke include unstable INR and low TTR in patients treated with a VKA; previous bleed or anaemia; alcohol excess and other markers for decreased therapy adherence; chronic kidney disease; elevated high-sensitivity troponin; and elevated N-terminal pro-B-type natriuretic peptide. Some have been incorporated into more recent stroke scores proposed for AF, such as the ATRIA (Anticoagulation and Risk factors In Atrial fibrillation), QStroke, and ABC-stroke scores. Biomarker-based stroke risk scores (e.g. ABC score) do not appear to confer long-term benefit over simple clinical scores such as CHA2DS2-VASc. In addition, stroke risk is not static, and regular review and reassessment of risk is needed during follow-up.

In the CHA2DS2-VASc score, the V criterion for ‘vascular disease’ is defined as ‘previous MI, peripheral artery disease, or aortic plaque’, since these are factors, which are more validated to confer an excess of stroke risk in patients with AF. Patients with mild coronary atheroma alone, or simply a history of angina, have not been definitively shown to have an excess of stroke risk if no other CHA2DS2-VASc risk factors are present (hence do not score a point for the V criterion). Patients with a CHA2DS2-VASc score of ≥1 for men or ≥2 for women are likely to benefit from stroke prevention with specific treatment decisions for type and duration of associations of antithrombotic agents based on the clinical setting and patient profile (elective PCI or ACS, risk factor for CAD progression, and coronary events, risk of bleeding) possibly incorporating patient preferences.

Clinical risk scores for bleeding

Several bleeding risk scores have been developed, mainly in patients on VKAs. These include HAS-BLED (hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, labile INR, elderly (>65 years), drugs/alcohol concomitantly (1 point each)), ATRIA, ORBIT (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), and more recently, the ABC (age, biomarkers, clinical history) bleeding score, which includes selected biomarkers. While stroke and bleeding risks correlate with each other, the HAS-BLED score is a superior predictor of bleeding risk compared with the CHADS2 [congestive heart failure, hypertension, age, diabetes, stroke (doubled)] or CHA2DS2-VASc scores.

The simple HAS-BLED score has similar or a superior bleeding risk assessment to other proposed scores, some of which are more complex. This is particularly evident amongst VKA users, given that other scores (Hemorrhage, ATRIA, ORBIT) do not consider quality of anticoagulation control, i.e. labile INR as a bleeding risk. In another trial cohort, the ORBIT score demonstrated the best discrimination and calibration when tested in the RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy with dabigatran etexilate) trial, whereby all the scores demonstrated, to a variable extent, an interaction with bleeding risk associated with dabigatran or warfarin. On the other hand, the biomarker-based ABC bleeding risk score did not appear to confer long-term benefit over a more simple clinical score such as HAS-BLED. Similarly, the PRECISE DAPT score has been developed to assess the out-of-hospital bleeding risk in patients in whom DAPT but not OAC is indicated; however, this score currently does not provide useful information on the additional bleeding risk in patients in whom both OAC and DAPT are concomitantly indicated.

Of note, the HAS-BLED, ORBIT, and ABC scores have also been validated in patients on NOACs. The HAS-BLED score has been validated in patients with CAD treated with coronary stenting. A high bleeding risk score should generally not result in withholding OAC, and is appropriately used to ‘flag up’ patients at high risk of bleeding (HAS-BLED score >3) for more regular review and earlier follow-up.

Of importance, modifiable bleeding risk factors (e.g. uncontrolled blood pressure, concomitant antiplatelet or NSAID use, alcohol excess) should always be identified and corrected at every patient contact. In addition, bleeding risk is not static, and regular review and reassessment of risk is needed during follow-up, especially since an adverse change in (say) HAS-BLED score is associated with excessive bleeding risk particularly in the initial 3 months.

When managing patients with AF undergoing PCI/stenting, it is recommended to concomitantly assess stroke, bleeding, and ischaemic event risks (using validated tools such as the REACH, Syntax, and GRACE scores). A recent retrospective analysis confirmed the value of the Syntax and GRACE scores for identifying higher risks of coronary events and mortality, respectively, in AF patients with coronary stenting.

What is the practical application of formal bleeding risk assessment? An approach based only on modifiable bleeding risk factors alone is an inferior assessment compared with a formal bleeding risk score. A high (uncorrectable) bleeding risk may flag up the patient for earlier review and follow-up (e.g. 4 weeks rather than 4–6 months), as well as lead to shortening of TAT with earlier switch to DAT in case of estimated low atherothrombotic risk as calculated with the Syntax or REACH score, although prospective validation is missing in such combination scenarios. A similar clinical setting may lead to the decision to discontinue all antiplatelets and provide anticoagulation as monotherapy earlier (e.g. after 6 months instead of 1 year).

In the small subset of AF patients undergoing PCI with elevated bleeding risk and a relatively low stroke risk (CHA2DS2-VASc of one in males or two in females), one option would be to treat with only DAPT, without OACs, from the onset (although in ACTIVE-W, derived from prospective registries. Since the US FDA released a safety alert communication in July 2015 due to reports of adverse patient outcomes, the use of LARIAT in the US has dropped significantly (https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/esurom454501.htm).

In summary, LAA occlusion may be considered in selected AF patients with absolute contraindications to any OAC. Trial data supporting use of shorter duration TAT or even DAT in these patients in general (as discussed above), as well as the recommendation for short duration OAC after the procedure in patients treated with Watchman device, makes the rationale for implanting these devices solely for the reason that the AF patient requires PCI unclear.
there were numerically more MIs with aspirin plus clopidogrel compared with warfarin.\textsuperscript{138}

The TIMI-AF score has recently been proposed in VKA-naive patients with AF to assist in the prediction of a poor composite outcome and guide selection of anticoagulant therapy by identifying a differential clinical benefit with a NOAC or VKA.\textsuperscript{139} This complex score includes 11 items (including a history of MI) with a maximum integer score of 17 and needs to be more specifically validated in AF patients with ACS and/or undergoing percutaneous coronary or valve interventions. In a ‘real world’ cohort of VKA-experienced AF patients, the TIMI-AF score was found to have limited usefulness in predicting net clinical outcomes over a long-term period of follow-up and was not superior to CHA\textsubscript{2}DS\textsubscript{2}-VASc and HAS-BLED for identifying low-risk AF patients.\textsuperscript{140} Another simple score, the 2MACE [two points for Metabolic Syndrome and Age \textgreater 75; one point for MI/revascularization, Congestive heart failure (ejection fraction \textless 40%), thrombo-embolism (stroke/transient ischaemic attack)] score has also been proposed for the prediction of MACE, but has not been validated in AF patients undergoing PCI.\textsuperscript{141,142}

## Optimizing management

Table 3 summarizes the key points outlined in major European and American guidelines in patients undergoing percutaneous coronary interventions when on oral anticoagulation.

From the OAC perspective, the main management aspects pertain to the introduction of the NOACs. The latter drugs have changed the landscape of stroke prevention management amongst patients with AF, although some regional differences are evident.\textsuperscript{143}

Table 4 provides a summary of the antithrombotic management differences between a VKA and NOAC in relation to management of AF patients presenting with an ACS and/or undergoing PCI/stenting.

### Elective percutaneous cardiovascular intervention for stable coronary artery disease

Since the publication of the 2014 consensus document, several studies (mostly observational) have been published.\textsuperscript{8–32,34–37,39,146,147} As opposed to some studies where only patients with ACS have been included, none reported exclusively on AF patients undergoing PCI in the context of stable CAD. The preferential role of radial access in patients on OAC with VKA undergoing PCI is corroborated by a retrospective, single-centre analysis of 97 patients undergoing PCI (proportion of stable CAD not reported) with INRs >2.0, in whom total and major BARC bleeding and need for transfusions was significantly lower with radial when compared with femoral approach.\textsuperscript{150}

Limited data are available for AF patients undergoing PCI while on NOAC. In the phase IIa, multicentre D-fine clinical trial, 50 patients undergoing elective PCI were randomized to either pre-procedural dabigatran 110 or 150 mg bid or standard intra-procedural UFH.\textsuperscript{151} Following PCI, dabigatran appeared to provide insufficient anticoagulation, as shown by significantly higher values compared with UFH of prothrombin fragment 1 + 2 and thrombin-antithrombin complexes.\textsuperscript{152} Clinical outcomes tended to be higher in the dabigatran group, where 5 out of 40 (12.5%) required bail-out anticoagulation when compared with 1 out of 10 (10%) in the standard UFH group.\textsuperscript{151} No significant bleeding was observed in either group.\textsuperscript{151}

In a phase IIa, multicentre trial (X-plorer), 108 patients undergoing elective PCI and on stable dual antiplatelet therapy of aspirin and clopidogrel were randomized to a single dose of either rivaroxaban 10 mg, rivaroxaban 20 mg, rivaroxaban 10 mg plus intravenous bolus of UFH, or standard UFH.\textsuperscript{152} Patients with an indication for OAC were excluded. Following PCI, in all groups receiving rivaroxaban anticoagulation was effectively suppressed, comparably to standard UFH, as shown by the low plasma levels of the fragment 1 + 2 and thrombin-antithrombin complex.\textsuperscript{152} No patients in the three rivaroxaban arms required bail-out antithrombosis mediation and/or had clinical signs of catheter-related thrombosis.\textsuperscript{152} No significant bleeding was observed in either group up to 30 days after PCI.\textsuperscript{152}

Because of the inconsistency of the results reported with the two different NOACs (dabigatran and rivaroxaban), performing elective
PCI in patients with stable CAD on ongoing uninterrupted NOAC monotherapy is currently not recommended. Also, uncertainty exists on the true level of anticoagulation with NOAC raises uncertainty when the treatment of a thrombotic complication is needed, e.g. administration of glycoprotein IIb/IIIa (GPI) inhibitors or the optimal use of additional UFH.

Whereas intra-procedural anticoagulation with UFH should be carried out as per usual practice in AF patients on NOAC, uncertainty exists on whether additional UFH should be given to patients on OAC with VKA undergoing PCI while the INR is >2.0. In a case-control study on 336 patients undergoing transradial coronary angiography, the incidence of both early (24-h) and late (30-day) radial artery occlusion was significantly higher in the ongoing warfarin group, given that the slower and less intense platelet inhibition compared with UFH plus glycoprotein (GPI), may be a preferable option for intra-procedural anticoagulation on ongoing effective VKA is uncertain. Limited, observational data suggest that bivalirudin may indeed be preferred, given that the 30-day occurrence of major bleeding and MACCE was shown to be lower in 51 patients receiving bivalirudin (stable CAD in 47%) when compared with 87 treated with UFH plus GPI (stable CAD in 15%), who were identified out of 1104 on warfarin undergoing PCI in two study protocols. While there is a general agreement on the need for, at least initial, TAT of OAC plus DAPT of aspirin and clopidogrel in most AF patients undergoing PCI, the optimal timing and schedule for antiplatelet agents administration is not established. In patients not on OAC and stable aspirin therapy, clopidogrel may be administered either prior to or during PCI with no apparent differences in outcomes with the two strategies. Given that TAT is associated with an increased risk of bleeding, it may be considered to withhold the additional antiplatelet agent until indication for PCI arises from diagnostic coronary angiography.

The time required to reaching effective platelet inhibition with oral loading of clopidogrel is approximately 2 to 6–8 h, depending on whether a 600 or 300 mg dose, respectively, is given, as opposed to either intravenous or oral aspirin, which has a nearly immediate antiplatelet effect. When carried out, pre-treatment with both aspirin and clopidogrel should preferably include loading with 300 mg, given that the slower and less intense platelet inhibition compared with 600 mg may reduce the initial risk of bleeding in patients naive to antiplatelet therapy and on ongoing OAC.

No additional data are available on GPI use in AF patients treated with OAC undergoing PCI. As for non-OAC patients with stable CAD, indication for GPI remains essentially limited to bail-out situations where however, further care is advised, given the previously reported substantial risk of major bleeding in the absence of a significant benefit on MACCE. When abciximab is used, bolus only, either intracoronary or intravenous, may be considered because of possible superior safety compared with conventional intravenous bolus plus infusion strategy. Use of GPI as per standard practice can be considered for patients on NOAC when timely discontinuation before PCI has been carried out.

### Acute management

No randomized trials have specifically studied periprocedural management in anticoagulated patients developing an ACS and undergoing acute angiography with or without PCI. The following suggestions are based on observational studies and expert opinion and are in accordance with recent ESC guidelines. All AF patients taking OAC developing an ACS should receive aspirin immediately [150–300 mg oral loading dose or 75–150 mg i.v. (intravenous)]. To reduce the risk of bleeding, one option is to postpone the

---

**Table 3** Summary of main recommendations in recent guidelines

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>ESC myocardial revascularization 2017</th>
<th>ESC AF 2016</th>
<th>ACC/AHA 2016 combined OAC/APT</th>
<th>ESC 2017 DAPT update</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use of periprocedural aspirin and clopidogrel</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Preferred use of DES</td>
<td>++</td>
<td>–</td>
<td>–</td>
<td>++</td>
</tr>
<tr>
<td>Recommendations according to the type of platform (DES vs. BMS)</td>
<td>n/a</td>
<td>–</td>
<td>++</td>
<td>n/a</td>
</tr>
<tr>
<td>Use of ticagrelor or prasugrel</td>
<td>–</td>
<td>n/a</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Use of specific score for ischaemic or bleeding risks</td>
<td>++</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>DAT as an alternative to TAT in CHA2DS2-VASc score ≤1</td>
<td>++</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>DAT as an alternative to initial TAT</td>
<td>+</td>
<td>+</td>
<td>n/a</td>
<td>++</td>
</tr>
<tr>
<td>1–6 months as the default strategy in ACS patients</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Use of NOAC</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Stopping aspirin rather than clopidogrel</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Stopping all antiplatelet therapy after 1 year</td>
<td>n/a</td>
<td>n/a</td>
<td>++</td>
<td>n/a</td>
</tr>
<tr>
<td>++, recommended; +, may be considered; –, not recommended by the relevant guideline; ACS, acute coronary syndrome; BMS, bare-metal stent; DAT, dual therapy; DES, drug-eluting stent; n/a, box means not stated; NOAC, non-vitamin K antagonist oral anticoagulant; TAT, triple therapy.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 4  Summary of the antithrombotic management differences between a VKA and NOAC in patients undergoing elective PCI

<table>
<thead>
<tr>
<th></th>
<th>VKA</th>
<th>NOAC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Periprocedural management</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Anticoagulation (see Figure 1) | Because of the reduced risk of bleeding, VKA should not be interrupted (or bridged with heparin). | Elective PCI  
• Because of the undefined intra-procedural protection against thrombotic events of NOAC, timely (12–24 h in advance, based on renal function and agent) interruption is preferred.  
• Depending on renal function and agent used (e.g. Dabigatran has high renal dependency for its excretion), cessation for 24–48 h may be considered.  
• No bridging is recommended.  
**Emergency PCI**  
• NOACs need not to be interrupted. |
| Vascular access | Because of the reduced risk of access-site bleeding complications, the radial approach should be preferred. | Whether NOAC is interrupted or not, UFH should be administered as per usual practice |
| Additional intra-procedural UFH | To prevent radial artery occlusion, and possibly limit the occurrence of intra-procedural thrombotic complications, UFH should be administered. | Standard dose UFH (70–100 U/kg) should be given |
| Dose of additional intra-procedural UFH | To limit the risk of bleeding (in ongoing VKA), reduced dose (30–50 U/kg) should be given. |                                                                      |
| Use of bivalirudin | Because of the observation of superior safety, and possibly also efficacy, it may be considered in accordance with prescribing label. Specific data in patients on OAC are limited. |                                                                      |
| P2Y_{12}-receptor inhibitor | Because of the potential increased risk of bleeding with prasugrel and ticagrelor in stable CAD patients on OAC, clopidogrel is generally recommended.  
• Consider pre-treatment with at least one antplatelet agent in most cases.  
• Where coronary anatomy is known or in emergency cases, whereby a decision for PCI is likely, pre-treatment with a P2Y_{12}-receptor inhibitor can be considered.  
• Small numbers of prasugrel were used in the PIONEER-AF trial. In REDUAL-PCI, 12% were prescribed ticagrelor, which did not show excess bleeds when used with dabigatran as DAT. | Whether NOAC is interrupted or not, 300 or 600 mg loading dose should be selected as per usual practice due to limited data. |
| Dose of P2Y_{12}-receptor inhibitor | Because clopidogrel should be given in advance of PCI, 300 mg loading should generally be preferred to limit the risk of bleeding (with ongoing VKA). | Because of the observed increase in major bleeding, with no benefit in ischemic outcomes, GPI should not be used, except for bail-out, in life-threatening situations. |
| Use of GPI | Because of the observed increase in major bleeding, with no benefit in ischemic outcomes, GPI should not be used, except for bail-out, in life-threatening situations. | Use of GPI as per standard practice can be made for patients on NOAC when timely discontinuation before PCI has been carried out. |

*Continued*
Table 4  Continued

<table>
<thead>
<tr>
<th>Post-procedural management</th>
<th>VKA</th>
<th>NOAC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antithrombotic regimen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intensity of OAC</td>
<td>In patients on TAT, INR at the lower end of therapeutic range (2.0–2.5) should be targeted, with high TTR (&gt;65–70%). With DAT, conventional therapeutic range (2.0–3.0) may be targeted, with high TTR (&gt;65–70%).</td>
<td>Low dose dabigatran 110 mg bid and full dose apixaban 5 mg bid and edoxaban 60 mg od should be selected to optimize risk-benefit ratio, if part of a TAT regime. With DAT, dabigatran 150 mg plus P2Y12 is preferred, unless dose reduction criteria for dabigatran are present in accordance with its label. Reduced dose rivaroxaban 15 mg od rather than full dose 20 mg od may be considered to reduce the risk of bleeding. Pending further data in the PCI setting, reduced dose apixaban and edoxaban are only used in accordance with their respective approved labels. After withdrawal of one antiplatelet agent, full dose apixaban 5 mg od and edoxaban 60 mg od should be used, whereas reduced dose rivaroxaban 15 mg od should be replaced by full dose 20 mg od if Creatinine clearance is ≥50 mL/min. Decision on whether or not to increase ongoing dabigatran 110 mg bid to 150 mg bid should be left at the discretion of the attending physician, based on the individual risk of stroke and bleeding and the goal of antithrombotic therapy.</td>
</tr>
</tbody>
</table>

| Intensity of OAC during subsequent antithrombotic regimen after 12 months | Target INR should be 2.0–2.5 after withdrawal of one antiplatelet agent, with high TTR (>65–70%). |     |

| Duration of TAT | Based on the risk of stent thrombosis/recurrent cardiac events and bleeding, 1 to 3–6 months should be selected. Especially with ACS patients, ideally try to keep TAT to 6 months, but shorten to 3 months if high bleeding risk (e.g. HAS-BLED ≥3). |     |

| Dose of aspirin | Low-dose 75–100 mg od should be used to reduce the risk of gastrointestinal bleeding. |     |

| Use of gastric protection | Proton-pump inhibitors should be routinely administered throughout TAT. |     |

| Subsequent antithrombotic regimen after triple therapy | Upon completion of initial course of TAT, one antiplatelet agent, either aspirin (preferably), or clopidogrel should be withdrawn and DAT with OAC plus single antiplatelet therapy continued. |     |

| Duration of subsequent antithrombotic regimen | Combined OAC plus single antiplatelet regimen should be continued up to 12 months after PCI. |     |
|                                               | • Approximately 6 months is the accepted risk period for stent thrombosis, although limited data are available for AF patients. |     |

| Long-term management Antithrombotic regimen |     |     |
Table 4  Continued

<table>
<thead>
<tr>
<th>VKA</th>
<th>NOAC</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Upon completion of 1-year of combined OAC plus (dual and single) antiplatelet therapy, OAC should be continued as monotherapy.</td>
<td>• Full dose rivaroxaban 20 mg od, apixaban 5 mg bid, or edoxaban 60 mg od should be given, unless standard criteria for dose reduction are present.</td>
</tr>
<tr>
<td>• In patients at increased risk of stent thrombosis and/or recurrent cardiac events or of catastrophic consequences in the event this occurs continuation of combined OAC plus single antiplatelet agent (either aspirin or clopidogrel), may be considered, but has to be balanced against risk of serious bleeding.</td>
<td>• Low (110 mg bid) or high (150 mg bid) dose of dabigatran should be selected based on the individual risks of stroke and bleeding and the goals of antithrombotic therapy.</td>
</tr>
</tbody>
</table>

Long-term management
Intensity of OAC during long-term management

Conventional INR target 2.0–3.0 should be prescribed, with TTR >65–70%.

For details and references, see text.

bid, twice daily; CAD, coronary artery disease; DAT, dual antithrombotic therapy; GPI, glycoprotein Iib/IIIa inhibitor; INR, international normalized ratio; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; od, once daily; PCI, percutaneous coronary intervention; TAT, triple antithrombotic therapy; TTR, time in therapeutic range; UFH, unfractionated heparin; VKA, vitamin K antagonist.
The administration of P2Y12 inhibitors to the time of PCI, when the anatomy is known.165

Oral anticoagulation is a relative contraindication for fibrinolysis. When anticoagulated patients present with a STEMI, they should be triaged for primary PCI regardless of the anticipated time to PCI-mediated reperfusion.164 Primary PCI via a radial approach is strongly recommended166 and clopidogrel is the P2Y12 inhibitor of choice (600 mg loading dose given at the time of primary PCI).164

The more potent P2Y12 inhibitors prasugrel and ticagrelor are generally not routinely recommended in anticoagulated patients due to their increased bleeding risk in combination with aspirin.6,165,167 Anticoagulated patients undergoing primary PCI should receive additional low-dose parenteral anticoagulation regardless of the timing of the last dose of OAC (VKA or NOAC) (e.g. enoxaparin 0.5 mg/kg i.v. or UFH 60 IU/kg).165

In NSTE-ACS patients undergoing an immediate invasive strategy (i.e. <2 h from symptom onset), periprocedural treatment should be as in STEMI patients. If invasive treatment is delayed, it is still suggested to perform PCI without interruption or discontinuation of VKAs or possibly, NOACs.58,165 As discussed above, an uninterrupted strategy was not associated with an increase in bleeding or major cardiovascular events compared with bridging therapy.58,168 In patients on VKAs, it is suggested either not to administer additional intraprocedural UFH if INR value is >2.5 or to consider a lower UFH dose regimen.165 In patients on NOACs, additional intraprocedural low-dose parenteral anticoagulation (e.g. enoxaparin 0.5 mg/kg i.v. or UFH 60 IU/kg) should be added irrespective of the time of the last administration of NOAC.165 GPIs should be avoided unless for bail-out situations. The new bioabsorbable vascular scaffolds should not be used in patients on OAC due to their higher thrombotic risk and need for a longer DAPT duration.169

### Post-procedural and post-discharge therapy

As regards the anti-thrombotic treatment to be prescribed at discharge, most of the additional evidence published since 2014 reports that TAT of OAC with either VKA or NOAC is consistently associated with an increased risk of major or total bleeding compared with other regimens with more heterogeneous effect on MACCE.8–32,34–37,39,146,147 The several limitations of observational studies, including lack of randomization, small size, insufficient information on treatment adherence, quality of OAC and limited absolute number of events, preclude definitive conclusions, especially regarding efficacy.

For most patients, TAT in the form of OAC, aspirin and clopidogrel should be considered for 1–6 months after an ACS.2,164,165 The optimal duration of such TAT depends on the patient’s ischaemic and bleeding risks. Non-vitamin K antagonist oral anticoagulants as part of TAT or DAT are generally safer than VKA use, with respect to bleeding risk and is the preferred option in the absence of contraindications to these drugs.

*Three randomized trials* (WOEST, PIONEER AF PCI, and REDUAL PCI)39,40,148 showed that double therapy with a P2Y12 inhibitor and either VKA (WOEST) or a NOAC (PIONEER, REDUAL PCI) was safer with respect to bleeding than TAT. However, none of these studies were sufficiently powered for efficacy and the populations studied were a mixture of stable CAD and ACS patients. Of
AF Patients presenting with Elective PCI or ACS undergoing PCI

Concerns about thrombotic risk prevailing

Concerns about high bleeding risk prevailing

1: Periprocedural administration of aspirin and clopidogrel during PCI is recommended irrespective of the treatment strategy; as dual therapy, potent P2Y12 inhibitors (ticagrelor) may be combined with dabigatran

2: High atherothrombotic risk (For Elective PCI, use SYNTAX score; for ACS, GRACE score >140; stenting of the left main, proximal LAD, proximal bifurcation; recurrent MIs; stent thrombosis etc.) and low bleeding risk

3: Bleeding risk can be estimated using the HAS-BLED score; correct modifiable bleeding risk factors

Figure 2 Management algorithm for AF patients presenting with elective PCI or ACS undergoing PCI.

note, a signal of increased harm in the risk of stroke was apparent in the very low dose, i.e. 2.5 mg bid, rivaroxaban arm compared with conventional TAT(39). In the RE-DUAL PCI trial, a numerical trend for more thrombotic endpoints was also seen with the dabigatran 110 mg bid arm.39,40 Until more data are available, TAT is still the recommended as the initial treatment for the first month after PCI or an ACS in patients with a high ischaemic risk and a low bleeding risk.5

Trials with apixaban and edoxaban are ongoing. Because full-dose apixaban 5 mg bid and edoxaban 60 mg od were associated with significantly less major bleeding than warfarin in the ARISTOTLE (Apixaban for Reduction of Stroke and Other Thromboembolic Events in Atrial Fibrillation)170 and ENGAGE AF-TIMI 48171 trials for stroke prevention in non-valvular AF, these doses should generally be selected for TAT. Whereas safety of reduced-dose apixaban 2.5 mg bid and edoxaban 30 mg bid is likely higher, true efficacy in stroke prevention is unknown when these doses are used in the absence of factors qualifying patients for dose reduction, and should therefore generally not be used, even when DAPT of aspirin and clopidogrel is given in conjunction.

In patients with a low risk of bleeding, TAT may be extended longer, for to 3–6 months depending on the clinical scenario. After this period of TAT, OAC plus aspirin or (preferably) clopidogrel should be considered up to 12 months after PCI. After 1 year it is reasonable to maintain OAC alone.2,5

In cases of high bleeding risk, DAT (OAC plus aspirin or preferably, clopidogrel) may be considered from the time of discharge and continued for 1 year, followed thereafter by OAC alone.2,5 When NOACs are used, in general, dose reduction below the approved doses for stroke prevention is not recommended. The dose intensity of VKA should be carefully monitored with an INR in the lower part of the recommended range, and to ensure good quality anticoagulation control, as reflected by high TTR (e.g. >65–70%). Gastric protection with a proton pump inhibitor (PPI) is recommended in patients on triple therapy and in high bleeding risk patients on double therapy.165

As regards the optimal duration of TAT, especially with the aim of reducing the risk of bleeding, both the prospective, randomized ISAR-TRIPLE trial147 and the observational data by Koskinas et al.20 have provided additional information. In the ISAR-TRIPLE trial,147 614 patients receiving concomitant aspirin and VKA after PCI (for stable CAD in approximately 65%) with implantation of new-generation DES in about 80% of cases, were randomized to either 6-
week or 6-month clopidogrel therapy. At 9-month follow-up, the composite in incidence of death, MI, definite stent thrombosis or major bleeding was comparable in the two groups.20 In the analysis by Koskinas et al.20 of the prospective Bern PCI registry, out of the 568 patients with indication for VKA and discharged on TAT, 245 (43%) were prescribed 1-month duration of treatment whereas the remaining 323 (57%) were prescribed 6-month after PCI with implantation of new-generation DES in about 60% of cases.20 At 1 year, the primary composite endpoint of cardiac death, MI, stroke, definite stent thrombosis, or major bleeding was comparable in the two groups.20 In the current era of new-generation, less thrombogenic DES, it appears therefore that duration of TAT in OAC patients may be limited to 1–3 months only. No data were available on the quality of OAC, nor on the recommended INR range (commonly 2.0–2.5), but observational data suggest that freedom from major bleeding events may indeed be inversely related to TTR values.8

Additional evidence on the regimen to adopt or prolong after the initial course of TAT has been concluded, is not available. As per accepted recommendations, withdrawal of one of the two antiplatelet agents, either aspirin (preferably) or clopidogrel, should be performed, and combination of ongoing OAC (either VKA or NOAC) should be continued up to 1 year. If reduced dose rivaroxaban 15 mg od was ongoing, full dose 20 mg od could be started when one antiplatelet agent is withdrawn. The decision whether or not to increase the dose of dabigatran from 110 to 150 mg bid should be left at the discretion of the attending care provider based on the patient’s overall risk of bleeding and stroke.

Post hoc analyses of the stroke prevention trials did not suggest reduced efficacy or increased harm when NOAC plus antiplatelet therapy was compared with VKA plus antiplatelet therapy.

Atrial fibrillation occurring early after percutaneous cardiovascular intervention in acute coronary syndrome patients

Approximately 10% of patients hospitalized for ACS and generally undergoing PCI plus stenting develop AF in the early phase.172 Although it is presently unclear whether new onset AF associated with ACS has the same risk as a prior history of paroxysmal AF,173 OAC should be generally prescribed according to the individual risk of stroke, usually in combination, at least for some time, with antiplatelet agents. Initiation of warfarin in OAC-naive patients, as generally are those developing AF in the context of an ACS, is associated with an increase risk of bleeding, which may result in the withdrawal of antithrombotic agents, therefore increasing the risk of thromboembolic events.174 In the absence of established factors requiring dose reduction, the appropriate dose of NOAC should be given, as discussed above.175

Long-term management

After 1 year of combined OAC and (dual and single) antiplatelet therapy has been completed, OAC monotherapy (either VKA or NOAC) should be continued long term. Based on historical data with warfarin,176 the efficacy of OAC monotherapy in secondary prevention after a coronary event appears at least comparable to standard aspirin. VKA monotherapy has been associated with significantly less major bleeding compared with combined VKA and antiplatelet therapy, with no difference in the risk of cardiovascular death, MI, or non-haemorrhagic stroke at 2 years.177 Extrapolation of the VKA results has been made for NOAC.

Given the lack of specific data, combined OAC and single antiplatelet agent, either aspirin or clopidogrel, may be considered long-term only in highly selected cases with a very increased ongoing ischaemic risk, when clinical and/or anatomical circumstances indicate a high risk of thrombosis and/or major cardiovascular events if stent thrombosis occur.

Consensus statements for the management of atrial fibrillation patients presenting with an percutaneous cardiovascular intervention and/or undergoing percutaneous cardiovascular intervention/stenting

In general, the period of TAT should be as short as possible, followed by OAC plus a single antiplatelet agent (clopidogrel 75 mg od, or alternatively, aspirin 75–100 mg od). The duration of TAT is dependent on a number of considerations: acute vs. elective procedures, bleeding risk (as assessed by the HAS-BLED score), type of stent (with a preference for new-generation DES or BMS). Suboptimal stent placement might also increase the risk for ischaemic events and should be avoided in selected cases by use of intracoronary imaging techniques.

In case, we refer to OAC, this can be with well-controlled adjusted-dose VKA (with TTR >70%) or with a NOAC.

General management considerations

In AF patients, stroke risk must be assessed using the CHA2DS2-VASc score, and bleeding risk should be assessed using the HAS-BLED score.

• Stroke and bleeding risk stratification is a dynamic process, and must be performed at regular intervals.
• Every effort should be made to address modifiable bleeding risk factors at every patient contact.
• Established bleeding scores, e.g. HAS-BLED, should be used to draw attention to modifiable bleeding risk factors and to identify the patients for earlier review and follow-up.
An initial period of triple therapy should be used in most AF patients undergoing PCI, depending on presentation (ACS vs. elective), stroke vs. bleeding risk, procedural considerations (e.g., disease severity) etc.

- Dual therapy with OAC plus one P2Y₁₂ inhibitor (usually clopidogrel) may be considered in patients who are predisposed to excessive bleeding risk and have low thrombotic risk.

In anticoagulated patients, pretreatment with antiplatelet therapy is appropriate if PCI planned.

- Clopidogrel is the P2Y₁₂ inhibitor of choice in anticoagulated patients; prasugrel and ticagrelor should be avoided in patients also receiving aspirin due to their higher bleeding risk if used in combination as part of a TAT regimen.

- In anticoagulated patients, postpone pretreatment with P2Y₁₂ inhibitors if the coronary anatomy is not known.

NOACs as part of TAT or DAT are safer than VKA (e.g., Warfarin) with respect to bleeding risk and is the preferred option in the absence of contraindications to use of these drugs.

- AF patients with CHA₂DS₂-VASc score ≥2 treated with a NOAC should continue their NOAC indefinitely, with addition of antiplatelets for up to 12 months after PCI/ACS.

DAT with rivaroxaban or dabigatran and a P2Y₁₂ inhibitor is associated with a lower risk of bleeding than TAT with warfarin.

- None have been sufficiently evaluated with respect to efficacy. When dabigatran is used as part of DAT, the standard doses of 150 mg bid should be used to reduce the risk of ischaemic events.

- As per prescribing label, dabigatran 110 mg bid can be considered in elderly patients, concomitant when PgP inhibitors (e.g., verapamil) are used, and in patients with high bleeding risk.

- Both dabigatran 150 mg or 110 mg bid have been shown to be non-inferior (and in the case of 150 mg bid, superior) to warfarin for stroke prevention in AF.

When rivaroxaban is used as part of DAT, reduced dose 15 mg od should be considered.

- The efficacy with respect to stroke prevention of this reduced dose in this population has not been sufficiently evaluated.

When apixaban or edoxaban are used as part of TAT or DAT, the standard dose (5 mg bid and 60 mg od, respectively, unless label-guided dose reduction is indicated) should be selected pending results of ongoing trials.

When VKA is given in combination with clopidogrel and/or low-dose aspirin, the dose intensity of VKA should be carefully regulated, with a target INR range of 2.0–2.5.

- Good quality anticoagulation is recommended, with a high time in therapeutic range (TTR >65–70%) aimed for.

In patients on VKA undergoing coronary angiography and/or PCI, an uninterrupted VKA strategy is at least as safe as interrupted VKA, and seems to be much safer than interrupted VKA with bridging anticoagulation.

Patients with AF and stable vascular disease (arbitrarily defined as being free from any acute ischaemic event or repeat revascularisation for >1 year) should be managed with OAC alone.
Radial access should be considered as the default approach for coronary angiography/intervention to minimize the risk of access-related bleeding depending on operator expertise and preference. Gastric protection with PPIs should be considered in all patients with OAC plus antiplatelet therapy.

Long-term antithrombotic therapy (beyond 12 months) is recommended with OAC in all patients.

- Combination OAC plus single antiplatelet therapy (i.e., aspirin) may sometimes be continued in very selected cases, e.g. stenting of the left main, proximal bifurcation, recurrent MIs etc.

**Elective or stable CAD**

For NOAC-treated patients undergoing elective PCI, timed cessation (e.g., >12–48 h) before intervention may be considered, depending on the agent and renal function (see text) and use of standard local anticoagulation practices periprocedurally.

- Early after PCI, such as the same evening or the next morning, NOAC therapy should be restarted.

In patients with stable CAD and AF undergoing PCI at low bleeding risk (HAS-BLED <2), TAT (OAC, aspirin 75–100 mg daily, clopidogrel 75 mg daily) should be given for a minimum of 4 weeks (and no longer than 6 months) after PCI following which DAT with OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75–100 mg/day) should be continued for up to 6–12 months.

In patients with stable CAD and AF undergoing PCI at high bleeding risk (HAS-BLED ≥3), TAT (OAC, aspirin 75–100 mg daily, clopidogrel 75 mg daily) or DAT consisting of OAC and clopidogrel 75 mg/day should be given for 1 month after PCI following which DAT with OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75–100 mg/day) should be continued for up to 6 months, beyond which patients would be managed on OAC alone.

- In patients at very high bleeding risk (e.g., recent bleeding event), aspirin may be omitted, and DAT with a NOAC and clopidogrel 75 mg/day continued for 3–6 months, beyond which patients would be managed on OAC alone.

Long-term antithrombotic therapy with OAC (beyond 12 months) is recommended in all patients.

- Combination OAC plus single antiplatelet therapy (i.e., aspirin) may be considered in only very selected cases with an increased ongoing ischaemic risk.

When the procedures require interruption of OAC for longer than 48 h in high-risk patients (i.e., TAVI or other non-PCI procedures at high bleeding risk), enoxaparin may be administered subcutaneously, although the efficacy of this strategy is uncertain.

- Bridging is often considered in patients with mechanical heart valves, recent stroke/venous thromboembolism (<3 months).

Pharmacodynamic data suggest that enoxaparin might be a better option than unfractionated heparin, because of the more predictable and stable level of anticoagulation.

- Such ‘bridging’ therapies may be associated with an excess bleeding risk, possibly due to dual modes of anticoagulation in the overlap periods.

- When NOACs are used, timing of any bridging therapy should be tailored based on renal function and the pharmacokinetics of the specific NOAC.
**NSTE-ACS including unstable angina and NSTEMI**

In patients on OAC developing a NSTE-ACS, aspirin loading should be as in STEMI, and clopidogrel is again the P2Y12 inhibitor of choice.

- As clopidogrel takes considerable time to achieve its maximal antiplatelet effect in unstable patients, clopidogrel without aspirin cannot be recommended in the acute or periprocedural phase.

- Pretreatment with P2Y12 receptor antagonists may be withheld until the time of coronary angiography in case of an early invasive strategy within 24 h.

- The use of ticagrelor or prasugrel in combination with OAC may only be considered under certain circumstances (e.g., definite stent thrombosis while on clopidogrel, aspirin, and OAC).

Administer unfractionated heparin or bivalirudin only as bailout (but avoiding GPIIb/IIIa inhibitors) or if INR<2 in a patient on VKA, balancing the acute need for additional antithrombotic therapy with the excess bleeding risk and the ‘thrombus burden’.

- Glycoprotein IIb/IIIa inhibitors should be avoided unless for bailout situations due to the increased risk of bleeding associated with their use.

TAT is still the recommended initial treatment for the first month after PCI or an ACS in AF patients with a high ischemic risk and a low bleeding risk. An early invasive strategy (within 24 h) should be preferred among AF patients with moderate to high-risk NSTE-ACS in order to expedite treatment allocation (medical vs. PCI vs. coronary artery bypass grafting) and to determine the optimal antithrombotic regimen.

In AF patients with ACS at low risk of bleeding (HAS-BLED 0–2), the initial use of TAT (OAC, aspirin and clopidogrel) should be considered for 3–6 months following PCI irrespective of stent type; this should be followed by long term DAT (up to 12 months) with OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75–100 mg/day).

In patients with ACS and AF at high risk of bleeding (HAS-BLED >3), the initial use of TAT (OAC, aspirin, and clopidogrel) should be considered for 4 weeks following PCI irrespective of stent type; this should be followed by long term DAT (up to 12 months) with OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75–100 mg/day).

- In patients at very high bleeding risk (e.g., recent bleeding event), aspirin may be omitted, and dual therapy with OAC and clopidogrel 75 mg/day continued for 3–6 months, beyond which patients would be managed with OAC alone.

Long-term antithrombotic therapy (beyond 12 months) with OAC, whether with VKA or NOAC, is recommended in all patients.

- Combination OAC plus single antiplatelet therapy (i.e., aspirin) may be considered in very selected cases, e.g., extensive multi-vessel CAD, last remaining patent coronary artery, stenting of the left main stem or a proximal bifurcation, recurrent MIs etc.

**Primary PCI**

When anticoagulated patients present with a STEMI, they should be triaged for primary PCI regardless of the anticipated time to PCI-mediated reperfusion.
Areas for future research

Dual antithrombotic therapy by omitting aspirin in secondary prevention after acute coronary syndrome in patients with atrial fibrillation

Although both the PIioneer-AF\textsuperscript{179,180} and RE-DUAL PCI\textsuperscript{40} trials have shown a benefit of DAT (i.e. a NOAC in combination with clopidogrel) over TAT some questions still remain and need to be answered. Both studies miss a DAT comparator with VKA plus Clopidogrel. Moreover, 15 mg rivaroxaban in combination with clopidogrel does not reflect current guidelines that the NOAC should be used in the lowest dose that has been tested for stroke reduction.\textsuperscript{5}

Finally, the use of potent P2Y\textsubscript{12}-inhibitors (ticagrelor or prasugrel) in combination with a NOAC in this indication is still not sufficiently proven, given that only 12% of patients in RE-DUAL PCI and a minority in PIioneer-AF had these drugs. A particular patient group for further research with these newer agents includes those with high on clopidogrel platelet reactivity, especially in patients with a high prevalence of comorbidity.\textsuperscript{181,182} Such high on treatment platelet reactivity may have implications for prognosis, and optimal management remains uncertain.\textsuperscript{183}

New anticoagulants and new antiplatelet agents on the horizon

The search for the ‘holy grail’ of anticoagulation, an agent that combines optimal efficacy with minimal bleeding diathesis, continues. Also, novel antiplatelet drugs that selectively inhibit arterial thrombosis without interfering with normal haemostasis may yet occur. New antiplatelet drugs interfering with the interaction of von Willebrand factor (VWF) with glycoprotein (GP) Ib\textsubscript{a}, and directed against GPVI, GPIIb/IIIa (integrin \(\alpha\text{IIb}\beta\text{3}\)), the thrombin receptor PAR-1, and the ADP receptor P2Y\textsubscript{12} are on the horizon.\textsuperscript{184}

The development of new anticoagulant drugs is also rapidly expanding, targeting other factors in the coagulation cascade, such as Factor XI and XII.\textsuperscript{185,186} Factor XI has emerged as a particularly promising target for new anticoagulants that may be even safer than the NOACs, given the reduced thrombosis in factor XI-deficient mice, and that congenital factor XI deficiency is associated with only a mild bleeding diathesis.\textsuperscript{187} A recent Phase II trial showed that, when compared with enoxaparin, factor XI inhibition by an antisense antibody reduced venous thromboembolism without increasing bleeding after elective knee arthroplasty.\textsuperscript{188} Whether these new drugs can be translated to thromboprophylaxis for AF patients in the ACS or PCI setting requires further investigation.

Supplementary material

Supplementary material is available at Europace online.

Conflict of interest: See Supplementary material online.
References


Downloaded from https://academic.oup.com/europace/advance-article-abstract/doi/10.1093/europace/euy174/5056658 by guest on 10 October 2018


Atrial fibrillation
Clopidogrel Trial with Irbesartan for prevention of Vascular score. The AMADEUS trial.
Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk stratification based only on modifiable bleeding risk factors against the HAS-BLED score.
Presentation with acute coronary syndrome: prospective multinational observational study (GRACE).


